Market Cap | 753.62M | P/E | - | EPS this Y | -89.70% | Ern Qtrly Grth | - |
Income | -36.55M | Forward P/E | -13.86 | EPS next Y | 40.20% | 50D Avg Chg | - |
Sales | 213.94M | PEG | 0.07 | EPS past 5Y | - | 200D Avg Chg | 49.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | -123.00% | 52W High Chg | -1.00% |
Recommedations | 2.80 | Quick Ratio | 1.85 | Shares Outstanding | 49.42M | 52W Low Chg | 217.00% |
Insider Own | 1.79% | ROA | -4.59% | Shares Float | 43.75M | Beta | -0.06 |
Inst Own | 103.00% | ROE | - | Shares Shorted/Prior | 1.52M/1.60M | Price | 15.25 |
Gross Margin | 89.01% | Profit Margin | -17.09% | Avg. Volume | 922,107 | Target Price | 15.35 |
Oper. Margin | -12.49% | Earnings Date | Feb 22 | Volume | 1,215,184 | Change | 0.00% |
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
Citigroup | Neutral | Aug 29, 22 |
Truist Securities | Hold | Aug 24, 22 |
HC Wainwright & Co. | Neutral | Aug 24, 22 |
Stifel | Hold | Aug 23, 22 |
Needham | Hold | Aug 23, 22 |
Cantor Fitzgerald | Neutral | Aug 23, 22 |
HC Wainwright & Co. | Buy | May 9, 22 |
Needham | Buy | Feb 25, 22 |
Needham | Buy | Nov 5, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Kopczynski Casey C. | Chief Scientific Off.. Chief Scientific Officer | Feb 17 | Option | 0.2 | 60,651 | 12,130 | 265,522 | 02/17/21 |